Xilone

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xilone

Property Description
Active Ingredient Prednisolone Acetate
Form Ophthalmic suspension, Oral suspension, Syrup
Pharmacological Class Corticosteroid (Glucocorticoid)
General Purpose Managing steroid-responsive inflammation
Origin Synthetic

What Type of Medicine is Xilone (Prednisolone Acetate)?

Xilone is a medication whose active component is Prednisolone Acetate, an entity classified as a potent, synthetic glucocorticoid within the broader corticosteroid pharmacological class. This compound is a man-made derivative of hydrocortisone, a hormone naturally produced by the body. Its fundamental therapeutic mission is to act as a powerful anti-inflammatory agent and immunosuppressive agent. This classification reflects its ability to comprehensively regulate the body's inflammatory and certain immune responses. This compound acts as a potent glucocorticoid, indicated for its anti-inflammatory properties. This therapeutic potency is utilized for controlling acute flares of inflammation.


Composition and Physical Forms of Prednisolone Acetate

The drug is formulated as a single-ingredient product (monotherapy) that delivers the active Prednisolone Acetate compound in various physical forms for specific delivery routes. Prednisolone Acetate is an ester form of prednisolone, which is prepared as a sterile ophthalmic suspension for highly localized delivery, commonly referred to as eye drops, or as an oral suspension or syrup for a diffused, systemic effect. The formulation often requires the active ingredient to be prepared as a microfine particle suspension, a distinguishing feature necessary because of the compound's limited solubility, ensuring optimal absorption across membranes, particularly in its topical ophthalmic presentation.


What is the General Therapeutic Purpose of this Glucocorticoid?

The overall general purpose of this glucocorticoid is to manage and control steroid-responsive inflammation and allergic conditions through rapid, powerful suppression of the underlying biological immune cascade. By directly intervening in the inflammatory process, the compound helps to stabilize small blood vessels and regulate the chemical messengers that cause swelling and tissue damage. This robust action is typically employed in scenarios requiring the rapid reduction of acute inflammation, such as managing severe non-infectious eye inflammation. This action provides relief from common symptoms such as severe swelling, persistent redness, and irritation linked to various unwanted inflammatory reactions.

Regulatory References

  1. MedlinePlus Information

What side effects are possible with Xilone?

Possible Side Effects and Safety Information

Xilone (a systemic corticosteroid) is associated with a range of possible side effects that are generally dose-related and influenced by the duration of therapy. The most common adverse effects observed across systemic corticosteroid use include increased appetite, weight gain, fluid retention, mood changes, and gastrointestinal irritation.

Serious and Clinically Significant Adverse Reactions

Serious reactions involve multiple organ systems due to the drug's effect on immunity and metabolism. These include:

  • Infections: Increased susceptibility to and masking of serious infections, such as septicemia and tuberculosis, due to immune suppression.
  • Cardiovascular/Metabolic: Worsening of pre-existing conditions like diabetes mellitus and hypertension; disturbances in fluid and electrolyte balance.
  • Musculoskeletal: Osteoporosis (bone thinning) and bone fractures, which is a key long-term risk; dose-related growth retardation in children and adolescents.
  • Ocular: Development or worsening of glaucoma and cataracts; reports of central serous chorioretinopathy (CSCR), which can lead to vision loss.
  • Psychiatric: Behavioral and mood disturbances, including depression, euphoria, and, infrequently, worrying symptoms like suicidal ideation.

Safety Restrictions and Monitoring

Regulatory documents mandate specific precautions. The drug is contraindicated in patients with a known hypersensitivity to the drug, active tuberculosis, peptic ulcer, or systemic infections including fungal and tropical worm infections, unless appropriate anti-infective therapy is being used. Patients with or a family history of diabetes, hypertension, glaucoma, or epilepsy require frequent monitoring during treatment. Given the risk of ocular effects, patients experiencing visual disturbances should be considered for ophthalmological assessment. The common adverse effects may be associated with more serious consequences in the elderly.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Prednisolone Acetate, primarily based on the ophthalmic suspension formulation, indicates a low risk for acute overdosage. Documented information states that acute overdosage of the product is unlikely to occur via the administration route and will not ordinarily cause acute problems or immediate toxic effects.

Due to this low acute toxicity classification, no specific acute, severe, or life-threatening outcomes are documented in the overdose sections of official labels. Similarly, no specific clinical signs or symptom clusters are listed in the regulatory documents as being associated with acute overdosage.

If the ophthalmic suspension is accidentally ingested, the official emergency response statement requires the individual to drink fluids to dilute the product. This procedural instruction is the mandated action described in the regulatory prescribing information. Given the low acute toxicity profile, immediate medical help is not explicitly mandated in the official overdose sections.

Furthermore, no specific antidote is explicitly documented for the management of an acute Prednisolone Acetate overdose. The standard regulatory approach emphasizes dilution and general supportive care.

Therapeutic Uses of Xilone

What Xilone Treats: Main Uses and Benefits

Xilone, a medication containing Prednisolone Acetate, is a type of corticosteroid commonly used to provide symptomatic relief. It is applied in addressing conditions involving heightened physiological activity and related systemic imbalance. Its primary purpose is to address situations where symptoms become acutely distressing or disruptive to patient functioning. The medication is generally applied in contexts where short-term symptomatic assistance is needed across multiple therapeutic domains.


The medication helps to address symptom clusters that may become intense or disruptive, especially those linked to inflammatory or irritative states. It is commonly used across conditions presenting with acute episodes, including certain distressing allergic manifestations, flares of certain autoimmune diseases like rheumatoid arthritis, and localized inflammation of the eye (e.g., uveitis, certain allergic conjunctivitis).

“It is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.”

This approach offers symptomatic relief that helps patients cope more steadily with difficult episodes. It assists with managing symptoms like widespread swelling (edema), pronounced redness, and persistent ocular irritation, thereby contributing to improved day-to-day comfort during symptomatic periods.

Symptom Focus: Acute or Episodic Changes

Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Absolute Contraindications (Who Must Not Use)

Xilone (Prednisolone Acetate) is contraindicated and must not be used by individuals with a known hypersensitivity to the active ingredient, any other corticosteroid, or any component of the specific formulation. The ophthalmic suspension is strictly prohibited for patients with most viral diseases of the cornea (such as epithelial herpes simplex keratitis), fungal diseases of ocular structures, or mycobacterial infection of the eye. Systemic formulations are contraindicated in patients with cerebral malaria or those on immunosuppressive doses receiving live or live attenuated vaccines.


Conditional Use and Restrictions

The medicine is approved for use in adults and specific pediatric populations; however, long-term systemic use in children requires close monitoring for effects on growth and development. Use requires great caution in patients with pre-existing glaucoma, necessitating frequent intraocular pressure (IOP) monitoring. Caution is also mandated for patients with a history of ocular herpes simplex and those with thin corneal or scleral tissue due to the risk of perforation. Xilone is classified as Pregnancy Category C, and its use is acceptable only if the potential benefit justifies the potential risk to the fetus. For nursing mothers, a regulatory decision is required to either discontinue the drug or discontinue nursing.

What should I know about interactions with other medicines?

The official interaction profile for Xilone focuses on how co-administered substances modify the medicine’s systemic exposure and physiological effects.

Pharmacokinetic and Exposure Modification

The clearance of the corticosteroid is principally affected by the CYP3A4 enzyme system. Co-administration with CYP3A4 Inhibitors (such as Ritonavir or Ketoconazole) may decrease clearance, which is documented to result in increased systemic exposure to the medicine. Conversely, CYP3A4 Inducers (such as Phenytoin or Rifampin) may increase clearance, leading to decreased systemic exposure.

Pharmacodynamic Interactions and Constraints

Interactions based on physiological effect include Antidiabetic Agents, where the corticosteroid may increase blood glucose concentrations, opposing the antidiabetic effect. Co-use with NSAIDs is documented to increase the risk of gastrointestinal side effects. The hypokalaemic effect of Potassium-Lowering Agents (e.g., Diuretics) is enhanced when co-administered. Cyclosporine co-administration may increase the activity of both agents, with reports of convulsions. For the ophthalmic suspension, there are formal contraindications for use in most viral diseases of the cornea, including epithelial herpes simplex keratitis, and in fungal or mycobacterial ocular infections. Official labeling notes that elderly subjects may exhibit higher plasma concentrations due to impaired metabolic clearance.

Mechanism of Action

Genomic Suppression of Pro-Inflammatory Mediators

Xilone (Prednisolone Acetate) acts as an agonist of the intracellular Glucocorticoid Receptor (GR). The activated drug-receptor complex moves into the cell nucleus where it initiates two parallel genomic processes. Transrepression actively blocks the genes for major inflammatory signals like COX-2 and various cytokines (e.g., IL-1, TNF-alpha), while transactivation up-regulates the production of anti-inflammatory proteins, such as Annexin A1. This combined action constitutes the primary mechanism that drives the suppression of the immune response at the cellular level.

Broad Blockade of the Arachidonic Acid Cascade

The newly synthesized Annexin A1 directly inhibits the enzyme Phospholipase A2 (PLA2), which is essential for releasing Arachidonic Acid—the precursor to local inflammatory mediators. By blocking this early step, the drug effectively stops the synthesis of both prostaglandins and leukotrienes simultaneously. This broad molecular interference contributes to the reduction of localized vascular permeability and the stabilization of cell membranes, limiting the physiological extravasation of fluid and cells.

Dosage and Administration Information

How to Use Xilone (Prednisolone Sodium Phosphate Oral Solution)—Official Administration Guidelines

Xilone, an oral solution containing prednisolone sodium phosphate, must be administered strictly according to standard guidelines to ensure correct use. Dosage requirements are highly variable and must be individualized based on the disease being treated and the patient's response.

Administration Scope

Instruction Type Official Guideline
Route Oral administration only.
Preparation No dilution is required. Must be taken with food or milk to minimize gastrointestinal irritation.
Measurement The dose must be accurately measured using the special dosing device provided with the product, not a household spoon.
Dosing Schedule The daily dose should preferably be taken as a single dose in the morning to align with the body’s natural cortisol rhythm, or whenever possible, as a single dose on alternate days to help minimize potential side effects.
Dosing Range Initial adult dosage typically ranges from 10 mg to 60 mg prednisolone base per day, depending on severity. The lowest effective dosage must be used for maintenance therapy.
Pediatric Use Dosing must be governed by clinical factors and disease severity, rather than strict age or weight ratios. For asthma, specific doses apply, such as up to 10 mg daily for children under 2 years.
Missed Dose If a once-daily dose is missed, take it as soon as possible. If it is near the next scheduled dose, skip the missed dose and resume the regular schedule. Do not take a double dose.

Discontinuation (Dose Tapering)

Corticosteroid therapy must not be stopped abruptly if the drug has been taken for prolonged periods (generally, greater than three weeks at supraphysiologic doses). Instead, the dose must be gradually reduced (tapered) by stages to allow the body's systems to recover, as directed by a healthcare professional.

Recent Clinical Evidence

Research evidence / Overview of Studies for Xilone (Prednisolone Acetate)


Evidence for Systemic Use in Acute Inflammation Flares

Research for the active ingredient in Xilone, Prednisolone Acetate, has been studied in its oral formulations in research exploring how symptoms change over time during periods of heightened symptom activity. This research often takes the form of short-term randomized controlled trials (RCTs) where the medication course was studied for periods typically lasting a few weeks. The trials included adults experiencing acute flare-ups of conditions characterized by fluctuating or episodic manifestations, such as specific allergic or autoimmune diseases, and examined how symptoms were measured. Researchers generally examined outcomes related to systemic or functional imbalance, tracking changes in both patient-reported outcomes describing perceived discomfort and objective measures like inflammatory biomarkers.

Evidence for Ophthalmic Use in Non-Infectious Ocular Inflammation

The research for Xilone as an ophthalmic suspension (eye drops) has been evaluated in settings focusing on localized inflammation. This evidence relies on short-term randomized controlled trials that examined patient-reported experiences and objective signs in both adults and children. The trials explored its use in conditions involving periods of heightened symptoms in the eye, such as uveitis and severe allergic conjunctivitis. Research also examined temporary physiological strain following certain eye surgeries. In these studies, researchers monitored outcomes linked to inflammatory or irritative states, such as standardized Ocular Inflammation Scores that quantify cell and flare counts in the eye, and tracking changes in Visual Acuity. Findings describe patterns observed in the studies related to fluctuations in these inflammatory scores over the short follow-up period.


Long-Term Evidence and Durability of Follow-up

For Xilone, research exploring short-term symptom changes is much more common than studies with extended follow-up. The majority of the highest-quality data focuses on the acute phase—the first few weeks of treatment—when the drug was studied for episodic or acute changes. Long-term outcomes related to the tracking of symptom activity after the treatment course ends are not well characterized by large, formal RCTs. Studies that monitor patients over longer periods, focusing on outcomes reflecting daily functioning or activity level, tend to be observational in nature.


Research Gaps and Areas of Uncertainty

One key limitation is that follow-up durations were limited in many short-term studies, which leaves long-term effects not fully established. Additionally, comparative evidence is sometimes lacking, meaning head-to-head trials against all similar treatments are not always available to define relative patterns. For the systemic use, heterogeneity (variability) across the inflammatory conditions studied means that findings were mixed, and certainty remains low regarding protocols for use across every single possible indication. Subgroup findings are uncertain, especially for vulnerable populations or patients with complex, overlapping health issues.

Key Studies & References Prednisolone Acetate Systemic Formulation DailyMed Drug Information (NIH/FDA Label)

Frequently Asked Questions (FAQ)

Common questions about Xilone (FAQ)

Q: Is Xilone the same kind of medication as prednisone or prednisolone?

A: Official product information states that Xilone's active ingredient is prednisolone sodium phosphate. This is a specific salt form of the glucocorticoid prednisolone. Prednisolone itself is the active substance produced when the body metabolizes the medicine prednisone.

Q: Is it normal to feel more energetic or anxious when taking Xilone?

A: Regulatory documents indicate that this medication can affect the central nervous system, and side effects include changes in mood and anxiety. It is important to recognize that individual responses to this medication may vary.

Q: Are there any specific foods or drinks I need to avoid while on Xilone?

A: Official guidance advises taking Xilone with food or milk to help reduce the potential for stomach irritation. Additionally, official guidance indicates that a healthcare professional may recommend dietary adjustments, such as a diet low in salt but high in potassium and calcium, due to the drug's effect on mineral balance.

Q: Is Xilone suitable for children, and are there different formulations for them?

A: Xilone is indicated for use in pediatric patients to treat certain conditions, such as allergic states. Official drug information confirms that dosage for pediatric patients is determined by the specific condition being treated and the patient’s clinical response.

Q: Can taking Xilone affect my sleep patterns or cause insomnia?

A: Official adverse reaction lists include insomnia, or difficulty sleeping, as a known side effect of systemic corticosteroids. To help minimize this effect, official information suggests taking the daily dose as a single dose, often in the morning.

Q: Are there any lab tests I need to monitor while taking Xilone?

A: Official safety information mandates that patients with pre-existing conditions like diabetes or high blood pressure will require frequent monitoring during treatment. A healthcare provider may order necessary lab tests to monitor the patient’s condition.

Q: Can Xilone cause mood changes or emotional instability?

A: Official prescribing information confirms that corticosteroids can cause various side effects affecting the mind. These include changes in behavior and mood, such as euphoria, severe depression, mood swings, and personality changes.

Q: Do older adults typically experience different side effects from Xilone compared to younger people?

A: Official regulatory documents caution that elderly subjects may exhibit higher plasma concentrations of the medicine due to potential differences in metabolic clearance. This may make them more likely to experience certain age-related side effects, such as bone problems, and thus requires careful monitoring.

Q: Why is Xilone used to treat so many different types of conditions?

A: Xilone's active ingredient is a glucocorticoid, a potent class of medicine that works broadly by reducing inflammation and altering the body's immune system response. This fundamental anti-inflammatory and immunosuppressive action makes it useful for treating a wide array of conditions that are responsive to steroid therapy.

Q: Can Xilone cause stomach upset or acid reflux?

A: Regulatory documents list gastrointestinal irritation as a known common adverse effect. Official administration guidelines recommend taking the medication with food or milk to help minimize gastrointestinal irritation.

Q: Are there any clinical studies on Xilone that the general public can access?

A: Yes, the official prescribing information for Xilone, which summarizes the clinical studies and evidence used for its approval, is publicly available on government websites such as DailyMed (NIH) and the FDA's website.

Q: Is Xilone safe to take if I have high blood pressure?

A: The medication requires caution in patients with high blood pressure (hypertension) and necessitates frequent monitoring. Official safety warnings indicate the drug has the potential to worsen or contribute to high blood pressure.

Q: Can Xilone affect my vision or cause problems with my eyes?

A: Yes, official safety information warns of potential clinically significant ocular risks, including the development or worsening of glaucoma and cataracts. If visual disturbances occur, an ophthalmological assessment may be warranted, according to safety information.

Q: Can Xilone interact with herbal supplements or vitamins?

A: Official regulatory guidance emphasizes the importance of informing the healthcare provider about all concurrent use of supplements or herbal products. This is crucial because potential interactions can affect how Xilone works or how it impacts the body.

Q: Is feeling dizzy or lightheaded a common side effect of Xilone?

A: Regulatory safety information confirms that dizziness is listed as a possible side effect of systemic corticosteroids. As with any drug, the frequency of this effect can vary among individuals.

Q: Is Xilone used to treat allergic reactions other than asthma?

A: Yes, official drug indications show that the medicine is used for a variety of severe or incapacitating allergic conditions. These include allergic rhinitis (hay fever), contact dermatitis, and certain drug hypersensitivity reactions, in addition to asthma.

Q: Can Xilone cause fluid retention or swelling in the hands and feet?

A: Yes, official adverse reaction information lists fluid retention as a known common side effect. This condition may be observed as swelling in areas such as the fingers, hands, feet, or lower legs.

Q: Is there a risk of developing dependence on Xilone?

A: Official warnings note that stopping the medication abruptly after prolonged use can cause steroid withdrawal symptoms and potentially lead to a condition called adrenal insufficiency. For this reason, the medication must be gradually reduced (tapered) by stages, as directed by a healthcare professional.

Q: What are the signs of adrenal suppression related to Xilone use?

A: If the body's natural steroid production is suppressed by the medication, sudden cessation can lead to symptoms such as extreme tiredness, weakness, weight loss, and an upset stomach. These symptoms may suggest insufficient natural steroid production and should be reported promptly to a healthcare provider.

Q: Can Xilone interfere with vaccinations?

A: Yes, regulatory documents warn that Xilone can lower the body's resistance to infection, which may reduce the effectiveness of vaccines. Specifically, patients taking immunosuppressive doses of the drug should not receive live or live attenuated vaccines.

Q: Why does Xilone sometimes cause an increased appetite?

A: Official product information lists increased appetite as a common adverse effect. As a glucocorticoid, the drug influences the body's metabolism and the way it handles fat and food intake, which can lead to this change in appetite.

Q: Are there different strengths of Xilone, and what do the numbers mean?

A: Yes, the oral solution is available in different strengths, which indicates the precise amount of active ingredient per dose volume. For example, a strength may state that there is 15 mg of prednisolone base in every 5 mL of liquid.

Q: Can I take Xilone if I have a history of stomach ulcers?

A: Official safety warnings indicate that a history of or presence of a peptic ulcer is a condition that requires caution with Xilone use. The drug is contraindicated (must not be used) in certain circumstances related to stomach ulcers.

Q: Can Xilone cause changes to the skin, like thinning or easy tearing?

A: Yes, official adverse reaction reports list skin changes as a possible side effect. These can include developing thin, fragile skin; slowed healing of cuts or bruises; and red or purple marks under the skin.

How should Xilone be stored and disposed of?

Storage and Disposal Conditions for Xilone (Prednisolone Acetate)

Official Storage Requirements

Xilone Syrup or Oral Suspension must be stored in a refrigerator (between 2 C and 8 C) prior to its first opening. It must be kept in the original container and outer carton to protect it from light. Once opened, the syrup has an in-use shelf-life and must be used within 3 months, stored below 25 C. The ophthalmic suspension should be stored upright between 15 C and 25 C and must not be frozen. The medicine must be kept out of the sight and reach of children.


Disposal

Any unused or expired product must be disposed of in accordance with local requirements. For most household disposal, the medicine should be mixed with an unappealing substance, sealed in a container, and thrown into the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xilone found in:

A-Z Index: